Pipeline

Anhedonia in Major Depressive Disorder

Anhedonia is a major depressive disorder that results in an inability to gain pleasure from normally enjoyable experiences. It is a core symptom in depression and is also frequently seen in people suffering with bipolar depression, schizophrenia, substance-abuse disorders, Parkinson’s disease, diabetes, and coronary artery disease. The habenula circuit in the epithalamus moderates dopamine, serotonin, and other neurotransmitter pathways. Its role in reward processing is well established, indicating a potential therapeutic pathway target for anhedonia in major depressiver disorder. G Protein-Coupled Receptor 139 (GPR139) is an orphan receptor in the habenula and a potential target for anhedonia in major depressive disorder therapeutic development.

NBI-1065846: An Investigational Therapy for Anhedonia in Major Depressive Disorder

NBI-1065846 is a potential first-in-class, investigational GPR139 agonist for the treatment of anhedonia in major depressive disorder.

Clinical Trials: Anhedonia in Major Depressive Disorder

Neurocrine Biosciences is currently conducting the TERPSIS™ study, a Phase 2 study to assess the efficacy and safety of NBI-1065846 in patients with anhedonia in major depressive disorder. For more information about this study, please visit studiesonmdd.com or ClinicalTrials.gov.